Search clinical trials for: ICP-022

Total 3628 results

Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

PCNSL | Secondary Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

CLL/SLL

China
Innocare Pharma Australia Pty Ltd

Completed

A Phase I Study of ICP-022 in Healthy Subjects

Rheumatoid Arthritis | Systemic Lupus Erythematosus

Australia
Shandong University

Not yet recruiting

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Immune Thrombocytopenia | Bruton's Tyrosine Kinase
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

ADME Study of [14C]ICP-022 in Healthy Males

Healthy Volunteers

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Peking University People's Hospital

Recruiting

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

B-cell Lymphoma

China
Castle Creek Pharmaceuticals, LLC

Completed

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

Healthy

United States
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Abant Izzet Baysal University

Completed

Investigation of the Effect of Specially Designed Insoles for Flat-footed Patients

Flat Foot [Pes Planus] (Acquired), Unspecified Foot

Turkey
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Adele Sparavigna

Unknown

Tolerance and Efficacy Evaluation of 3 Face Creams (FILLER)

Skin Aging

Italy
Diwakar Davar
Tesaro, Inc.

Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Ruijin Hospital

Recruiting

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

CNS Lymphoma

China
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Meghan Shea
GlaxoSmithKline

Recruiting

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Cervical Cancer | Recurrent Cervical Carcinoma | Metastatic Cervical Cancer | Metastatic Cervical Carcinoma | Advanced Cervical Carcinoma

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
University of Michigan
Medical University of South Carolina; University of Pennsylvania; National Institute... and other collaborators

Recruiting

Brain Oxygen Optimization in Severe TBI, Phase 3 (BOOST3)

Brain Injuries, Traumatic

United States, Canada
Henan Cancer Hospital

Recruiting

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Assiut University

Unknown

Intracranial Pressure Monitoring in Sever Traumatic Brain Injury Single Center Experience

Head Injury Trauma
Boston Scientific Corporation

Active, not recruiting

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing (MODULAR ATP)

Tachycardia, Ventricular | Arrhythmia, Ventricular

United States, Spain, Italy, United Kingdom, Netherlands, France, Czechia, Austria, Canada
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
InnoCare Pharma Inc.

Active, not recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
InnoCare Pharma Inc.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies

Mature B-cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Hematological Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Bladder Urothelial Cancer

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

Study of ICP-105 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Medical University of Vienna

Completed

Intracranial Pressure (ICP) Monitoring Following Traumatic Brain Injury (TBI)

Traumatic Brain Injury

Austria
Holland Bloorview Kids Rehabilitation Hospital

Completed

Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy

Cerebral Palsy

Canada
Javier Fandino, MD
Kaunas University of Technology

Completed

Non-invasive Brain Pressure Monitoring After Trauma or Hemorrhage

Traumatic Brain Injury (TBI) | Subarachnoid Hemorrhage (SAH)

Switzerland
Zagazig University

Recruiting

Multifidus Cervicis and Inter-Semispinal Plane Blocks in Analgesia After Cervical Spine Surgery

Cervical Spine Surgery

Egypt
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-033 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Oculogica, Inc.

Completed

Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure

Intracranial Pressure Increase

United States

Search clinical trials for: ICP-022

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations